{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:39:10Z","timestamp":1786977550065,"version":"build-2736575974"},"reference-count":26,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T00:00:00Z","timestamp":1575244800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010643","name":"Cidara Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010643","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Pharm in Drug Dev"],"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Rezafungin is a new echinocandin in development for treatment of candidemia and invasive candidiasis, and for prophylaxis of invasive fungal infections. Rezafungin is the first echinocandin to undergo definitive QT\/QTc study. This phase 1, single\u2010center, randomized, double\u2010blind trial was conducted to assess effects of intravenous rezafungin vs intravenous placebo (with moxifloxacin as positive control) on the QT interval of the electrocardiogram, corrected for heart rate by Fridericia's formula (QTcF), in healthy adults. Therapeutic (600 mg) and supratherapeutic (1400\u00a0mg) rezafungin doses were selected to achieve exposures 2.5\u2010fold higher than produced by the highest dose used in a phase 2 trial (400\u00a0mg once weekly). The primary end point was change in QTcF from baseline (\u0394QTcF) as a function of plasma concentration, assessed by comparing upper bounds of the 2\u2010sided 90% confidence interval. The estimated mean \u0394\u0394QTcF at the mean plasma concentrations for the rezafungin doses had upper bounds &lt;10 milliseconds, within the upper bound of the 2\u2010sided 90% confidence interval. Intravenous rezafungin up to 1400\u00a0mg in a single dose did not prolong QT interval and had no apparent effect on repolarization or QRS duration. Electrocardiogram results showed no clinically significant effects of concern. These findings support the continued development of rezafungin.<\/jats:p>","DOI":"10.1002\/cpdd.757","type":"journal-article","created":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T01:02:54Z","timestamp":1575334974000},"page":"456-465","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Lack of Effect of Rezafungin on QT\/QTc Interval in Healthy Subjects"],"prefix":"10.1002","volume":"9","author":[{"given":"Shawn","family":"Flanagan","sequence":"first","affiliation":[{"name":"Cidara Therapeutics Inc.  San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel B.","family":"Goodman","sequence":"additional","affiliation":[{"name":"BioTelemetry Research  Rockville Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alena","family":"Jandourek","sequence":"additional","affiliation":[{"name":"Cidara Therapeutics Inc.  San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"O'Reilly","sequence":"additional","affiliation":[{"name":"Celerion, Inc.  Tempe Arizona USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor","family":"Sandison","sequence":"additional","affiliation":[{"name":"Cidara Therapeutics Inc.  San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,12,2]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy210.2042"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy209.124"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2018.02.013"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.2.368-377.2000"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01541-16"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/cmi.12640"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01627-16"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00701-16"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.579"},{"key":"e_1_2_9_11_1","unstructured":"OngV FlanaganS WatsonD SadequeA.Absorption Distribution and Excretion of [14C]Rezafungin after Single\u2010Dose Intravenous (IV) Administration in Rats and Monkeys. Presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID); April 13\u201016 2019; Amsterdam The Netherlands."},{"key":"e_1_2_9_12_1","article-title":"Rezafungin Clinical Safety and Efficacy in the Treatment of Candidemia and\/or Invasive Candidiasis: Combined Results from the STRIVE Phase 2 Trial Parts A and B","author":"Thompson GR","year":"2019","journal-title":"Presented at Trends in Medical Mycology"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1086\/508873"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1G741"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2007.00812.x"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.896946"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg472"},{"issue":"2","key":"e_1_2_9_18_1","first-page":"598","article-title":"Suppression of transient outward potassium currents in mouse ventricular myocytes by imidazole antimycotics and by glybenclamide","volume":"298","author":"Hernandez\u2010Benito MJ","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_9_19_1","unstructured":"International Conference on Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Guidance for industry: E14 clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non\u2010antiarrhythmic drugs.https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM073153.pdf. Published 2005. Accessed March 23 2019."},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270010381498"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.4103\/0976-500X.103697"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.4236\/pp.2013.43052"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ739"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12046"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12078"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-016-2023-3"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx446"}],"container-title":["Clinical Pharmacology in Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.757","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpdd.757","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.757","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T22:32:55Z","timestamp":1694039575000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/cpdd.757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,2]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["10.1002\/cpdd.757"],"URL":"https:\/\/doi.org\/10.1002\/cpdd.757","archive":["Portico"],"relation":{},"ISSN":["2160-763X","2160-7648"],"issn-type":[{"value":"2160-763X","type":"print"},{"value":"2160-7648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,2]]},"assertion":[{"value":"2019-05-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}